DPP-4 Inhibitors in Clinical Practice

References

• . Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin Resistance as a Predictor of Age-Related Diseases. J Clin Endocrinol Metab. 2001;86:3574–3578
   PubMed Web of Science ®Google Scholar
• . Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–1346
   PubMed Web of Science ®Google Scholar
• . Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31( suppl 2):S262–S268
   PubMed Web of Science ®Google Scholar
• . Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol. 1990;162(4):1008–1014
   PubMed Web of Science ®Google Scholar
• . Chen M, Bergman RN, Porte D Jr. Insulin resistance and beta-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab. 1988;67(5):951–957
   PubMed Web of Science ®Google Scholar
• . Defronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes. 1979;28(12):1095–1101
   PubMed Web of Science ®Google Scholar
• . Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med. 1998;49:235–261
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846
   PubMed Web of Science ®Google Scholar
• . Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607
   PubMed Web of Science ®Google Scholar
• . Kahn SE. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86(9):4047–4058
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Prigeon RL, McCulloch DK, . Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42(11):1663–1672
   PubMed Web of Science ®Google Scholar
• . Perley M, Kipnis DM. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes. 1966;15(12):867–874
   Google Scholar
• . Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81(2):442–448
   PubMed Web of Science ®Google Scholar
• . Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52(3):581–587
   PubMed Web of Science ®Google Scholar
• . Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53( suppl 1):S119–S124
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415–431
   PubMed Web of Science ®Google Scholar
• . Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–3643
   PubMed Web of Science ®Google Scholar
• . Barroso I. Genetics of type 2 diabetes. Diabet Med. 2005;22:517–535
   PubMed Web of Science ®Google Scholar
• . Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab. 2008;34( suppl 2):S49–S55
   PubMed Web of Science ®Google Scholar
• . IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–593
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49(8):1711–1721
   Google Scholar
• . Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9):2137–2139
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Del Prato S, Bianchi C, Marchetti P. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev. 2007;23(7):518–527
   Google Scholar
• . Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD004654
   Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Ohkubo Y, Kishikawa H, Araki E, . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117
   PubMed Web of Science ®Google Scholar
• . Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28(3):388–395
   PubMed Web of Science ®Google Scholar
• . Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17–20
   PubMed Web of Science ®Google Scholar
• . Liebl A, Mata M, Eschwege E; ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type 2 diabetes in Europe. Diabetologia. 2002;45(7):S23–S28
   Web of Science ®Google Scholar
• . Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med. 2009;121(1):40–45
   PubMed Web of Science ®Google Scholar
• . McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46–58
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med. 2008;120(2):5–17
   PubMed Web of Science ®Google Scholar
• . Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157
   PubMed Web of Science ®Google Scholar
• . Moore B. On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906;1(1):28–38
   Google Scholar
• . Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Homberger E, Siegel EG, . Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492–498
   PubMed Web of Science ®Google Scholar
• . Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995;16(3):390–410
   PubMed Web of Science ®Google Scholar
• . Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008;34( suppl 2):S65–S72
   PubMed Web of Science ®Google Scholar
• . Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37(5):826–828
   PubMed Web of Science ®Google Scholar
• . Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15(9):1559–1570
   PubMed Web of Science ®Google Scholar
• . Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66(2):91–103
   PubMed Web of Science ®Google Scholar
• . Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006;3(3):159–165
   PubMedGoogle Scholar
• . Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf). 2009;70(3):343–353
   Web of Science ®Google Scholar
• . Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84(10):3434–3438
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–613
   PubMed Web of Science ®Google Scholar
• . Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3(5):365–372
   PubMedGoogle Scholar
• . Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17(2):161–171
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144(12):5145–5148
   PubMed Web of Science ®Google Scholar
• . Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140(11):5356–5363
   PubMed Web of Science ®Google Scholar
• . Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952–957
   PubMed Web of Science ®Google Scholar
• . Mentlein R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9–24
   PubMed Web of Science ®Google Scholar
• . Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab. 2007;21(4):497–516
   PubMed Web of Science ®Google Scholar
• . Tahrani AA, Piya MK, Barnett AH. Exenatide: incretin therapy for patients with type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism. 2008;3(6):671–690
   PubMedGoogle Scholar
• . Tahrani AA, Piya MK, Barnett AH. Management of type 2 diabetes: the GLP-1 pathway. Future Prescriber. 2008;9:18–24
   Google Scholar
• . Herman GA, Stevens C, Van DK, . Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688
   PubMed Web of Science ®Google Scholar
• . Bergman AJ, Stevens C, Zhou Y, . Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55–72
   PubMed Web of Science ®Google Scholar
• . Herman GA, Bergman A, Stevens C, . Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–4619
   PubMed Web of Science ®Google Scholar
• . Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753–768
   PubMedGoogle Scholar
• . Lankas GR, Leiting B, Roy RS, . Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54(10):2988–2994
   PubMed Web of Science ®Google Scholar
• . Mu J, Woods J, Zhou YP, . Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704
   PubMed Web of Science ®Google Scholar
• . Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci. 2009;337(5):321–328
   Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Brazg R, Xu L, Dalla MC, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):186–193
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643
   PubMed Web of Science ®Google Scholar
• . Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–745
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205
   PubMed Web of Science ®Google Scholar
• . Nonaka K, Kakikawa T, Sato A, . Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–298
   PubMed Web of Science ®Google Scholar
• . Raz I, Chen Y, Wu M, . Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–550
   PubMed Web of Science ®Google Scholar
• . Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–180
   PubMed Web of Science ®Google Scholar
• . Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959–969
   PubMed Web of Science ®Google Scholar
• . Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329–1339
   PubMed Web of Science ®Google Scholar
• . Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571
   PubMed Web of Science ®Google Scholar
• . Mohan V, Yang W, Son HY, . Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106–116
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–1568
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Johnson J, Teng R, . Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569–583
   PubMed Web of Science ®Google Scholar
• . Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Round E, Swern AS, . Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14
   PubMedGoogle Scholar
• . Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/januvia/emea-combined-h722en.pdf. Accessed August 11, 2009
   Google Scholar
• . Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;(20):CD006739
   Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Chan JC, Scott R, Arjona Ferreira JC, . Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–555
   PubMed Web of Science ®Google Scholar
• . Migoya EM, Stevens CH, Bergman AJ, . Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol. 2009;16(1):e165–e170
   PubMedGoogle Scholar
• . Herman GA, Bergman A, Yi B, Kipnes M; Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939–1947
   PubMed Web of Science ®Google Scholar
• . Mistry GC, Bergman AJ, Luo WL, . Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol. 2007;47(2):159–164
   PubMedGoogle Scholar
• . Mistry GC, Bergman AJ, Zheng W, . Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008;66(1):36–42
   PubMed Web of Science ®Google Scholar
• . Bergman AJ, Cote J, Maes A, . Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49(4):483–488
   PubMedGoogle Scholar
• . Wright D, Maes A, Yi B, . Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin. Abstract. Clin Pharmacol Ther. 2009;79:P76
   Google Scholar
• . Miller JL, Migoya EM, Talaty JE, Bergman AJ, Xu Y, Zheng W, Gutierrez M, Wagner JA, Herman GA. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Abstract. Clin Pharmacol Ther. 2006;79:P24
   Google Scholar
• . Herman GA, Bergman A, Wagner J. An overview of the pharmacokinetic profile and the propensity for drug-drug interactions. Abstract. Diabetologia. 2006; suppl 1:A795
   Google Scholar
• . Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26(3):249–262
   PubMed Web of Science ®Google Scholar
• . Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Abstract presented at: American Diabetes Association; 2007
   Google Scholar
• . Boulton DW, Goyal A, Li L, Kornhauser DM, Frevert U. The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects. Abstract presented at: American Diabetes Association 68th Scientific Session; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Patel CG, Li L, Komoroski B, Boulton DW. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects. Abstract presented at: American College of Clinical Pharmacy (ACCP) Annual Meeting; October 14–17, 2007; Denver, CO. Poster 07–237c
   Google Scholar
• . Patel CG, Li L, Komoroski B, Boulton DW. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects. Abstract presented at: American College of Clinical Pharmacy (ACCP) Annual Meeting; October 14–17, 2007; Denver, CO. Poster 07–237a
   Google Scholar
• . Patel CG, Komoroski B, Li L, Boulton DW. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects. Abstract presented at: American College of Clinical Pharmacy (ACCP) Annual Meeting; October 14–17, 2007; Denver, CO. Poster 07–237b
   Google Scholar
• . Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ, ; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . Allen E, Hollander P, Li L, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes. Abstract presented at: EASD; Rome, Italy; 2008
   Google Scholar
• . Defronzo RA, Hissa MN, Garber AJ, . Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Presented at: American Diabetes Association; New Orleans, LA; 2009
   Google Scholar
• . Chen R, Pfützner A, Jadzinsky M, Paz-Pacheco E, Xu Z, Allen E. Initial combination therapy with saxagliptin and metformin improves glycemic control compared with either monotherapy alone in drug-naïve patients with type 2 diabetes. Abstract presented at: EASD; 2008
   Google Scholar
• . Rosenstock J, Aguilar-Salinas CA, Klein E, List J, Blauwet MB, Chen R. Once-daily saxagliptin monotherapy improves glycemic control in drug-naïve patients with type 2 diabetes. Abstract presented at: American Diabetes Association; San Francisco, CA; 2008
   Google Scholar
• . Ravichandran S, Chacra AR, Tan GH, Apanovitch A, Chen R. Saxagliptin added to a sulfonylurea is safe and more efficacious than up-titrating a sulfonylurea in patients with type 2 diabetes. Abstract. presented at: EASD; Rome, Italy; 2008
   Google Scholar
• . de HJ, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007;56(2):438–443
   Google Scholar
• . US Food and Drug Administration. Highlights of Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf. Accsesed October 10, 2009
   Google Scholar
• . Wolf R, Frederich R, Fiedorek F, . Evaluation of CV risk in the saxagliptin clinical trials. Presented at: American Diabetes Association; New Orleans, LA; 2009
   Google Scholar
• . Boulton D, Tang A, Patel C, . Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Abstract. Endocrine Abstracts. 2009
   Google Scholar
• . Patel C, Castaneda L, Fevert U, Li L, Kornhauser DM, Boulton DW. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Abstract presented at: American Diabetes Association; San Francisco, CA; 2008
   Google Scholar
• . Boulton DW, Adams D, Li L, . Maalox max®, famotidine or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects. Abstract presented at: ASCPT; Orlando, FL; 2008
   Google Scholar
• . Boulton DW, Li L, Patel CG, Komoroski BJ, Whigan D, Frevert EU, Kornhauser DM. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects. Abstract presented at: ASCPT; Orlando, FL 2008
   Google Scholar
• . Girgis S, You X, Li L, Maurer C, Whigan D, Boulton DW. Effect of simvastatin on the pharmacokinetics of saxagliptin in healthy subjects. Abstract presented at: 36th Annual Meeting of American College of Clinical Pharmacology; San Francisco, CA; 2007
   Google Scholar
• . Patel CG, Boulton DW, Brenner E, Royzman K, Li L. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects. Abstract. ACC Pharmacology. 2007
   Google Scholar
• . He YL, Serra D, Wang Y, Campestrini J, . Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46(7):577–588
   PubMed Web of Science ®Google Scholar
• . Hu P, Yin Q, Deckert F, . Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009;49(1):39–49
   PubMed Web of Science ®Google Scholar
• . Balas B, Baig MR, Watson C, . The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249–1255
   PubMed Web of Science ®Google Scholar
• . Mari A, Scherbaum WA, Nilsson PM, . Characterization of the influence of vildagliptin on model-assessed cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93(1):103–109
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Schweizer A, Rosenstock J, . Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10(10):931–938
   PubMed Web of Science ®Google Scholar
• . EMEA. Summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/jalra/emea-combined-h1048en.pdf. Accessed October 10, 2009
   Google Scholar
• . Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874–2880
   PubMed Web of Science ®Google Scholar
• . Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1):82–90
   PubMed Web of Science ®Google Scholar
• . Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11(6):589–595
   PubMed Web of Science ®Google Scholar
• . Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–895
   PubMed Web of Science ®Google Scholar
• . Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–515
   PubMed Web of Science ®Google Scholar
• . Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218–223
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Fonseca V, Zinman B, . Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–1155
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427–430
   PubMedGoogle Scholar
• . Garber AJ, Foley JE, Banerji MA, . Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047–1056
   PubMed Web of Science ®Google Scholar
• . Göke B, Hershon K, Kerr D, . Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892–895
   PubMed Web of Science ®Google Scholar
• . Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41(5):368–373
   PubMed Web of Science ®Google Scholar
• . Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83(2):233–240
   PubMed Web of Science ®Google Scholar
• . Pan C, Yang W, Barona JP, . Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25(4):435–441
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132–138
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38(6):423–428
   PubMed Web of Science ®Google Scholar
• . Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7(6):692–698
   Google Scholar
• . Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217–223
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(6):571–578
   PubMedGoogle Scholar
• . Scherbaum WA, Schweizer A, Mari A, . Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(8):675–682
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24(9):955–961
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166–174
   PubMed Web of Science ®Google Scholar
• . Scherbaum WA, Schweizer A, Mari A, . Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114–1124
   Google Scholar
• . Rosenstock J, Kim SW, Baron MA, . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–185
   PubMed Web of Science ®Google Scholar
• . Schepp W, Schmidtler J, Riedel T, . Exendin-4 and exendin-(9–39) NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2. Eur J Pharmacol. 1994;269(2):183–191
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–812
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Rosenstock J, Pi-Sunyer FX, . Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017–3022
   PubMed Web of Science ®Google Scholar
• . Tahrani AA, Piya MK, Barnett AH. Drug evaluation: vildagliptin-metformin single-tablet combination. Adv Ther. 2009;26(2):138–154
   PubMed Web of Science ®Google Scholar
• . Ahren B, Schweizer A, Dejager S, . Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236–1243
   PubMed Web of Science ®Google Scholar
• . Thuren T, Byiers S, Mohideen P, Goodman M. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment Abstract. Diabetologia. 2008;51:s36
   Google Scholar
• . He YL, Sabo R, Campestrini J, . The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol. 2007;63(7):677–686
   PubMed Web of Science ®Google Scholar
• . Ayalasomayajula SP, Dole K, He YL, . Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin. 2007;23(12):2913–2920
   PubMed Web of Science ®Google Scholar
• . He YL, Sabo R, Sunkara G, . Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol. 2007;47(8):998–1004
   PubMed Web of Science ®Google Scholar
• . He YL, Sabo R, Riviere GJ, . Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007;23(5):1131–1138
   PubMed Web of Science ®Google Scholar
• . He YL, Ligueros-Saylan M, Sunkara G, . Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008;48(1):85–95
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167–176
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA without causing weight gain or increased hypoglycaemia [published online ahead of print September 16, 2009]. Diabetes Obes Metab
   Google Scholar
• . NICE. The management of type 2 diabetes. http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed October 10, 2009
   Google Scholar
• . Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009;124(1):113–138
   PubMed Web of Science ®Google Scholar